Related Experiment Video

Updated: Jun 10, 2026

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices
02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

Development and progression of gastroesophageal varices in patients with chronic hepatitis C

Ivan Gentile1, Guglielmo Borgia

  • 1Department of Public Medicine and Social Security, University of Naples 'Federico II', Via S. Pansini, 5, I-80131 Naples, Italy. ivan.gentile@alice.it

Expert Review of Anti-Infective Therapy
|August 11, 2010
PubMed

Insights

Hepatitis C virus infection can lead to gastroesophageal varices. Low-dose pegylated interferon (PEG-IFN) therapy did not prevent new varix development or progression in patients with advanced liver fibrosis.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection is a primary cause of chronic liver disease and portal hypertension.
  • Portal hypertension can lead to gastroesophageal varices, increasing the risk of bleeding.
  • This study evaluated de novo varix development and progression in patients with chronic hepatitis C and advanced fibrosis.

Discussion:

  • The study analyzed demographic, clinical, laboratory, virological, endoscopic, and histological factors influencing varix development and progression.
  • Pegylated interferon-alpha2a (PEG-IFN-alpha2a) therapy was investigated for its potential to mitigate these risks.
  • Understanding these factors is crucial for managing patients at risk of variceal complications.

Key Insights:

  • Approximately 26% of patients developed de novo gastroesophageal varices during the study period.
  • Among patients with baseline varices, 35.2% experienced variceal progression or bleeding over 4 years.
  • PEG-IFN-alpha2a therapy did not demonstrate a significant effect on reducing the incidence or progression of gastroesophageal varices.

Outlook:

  • Further research is needed to identify effective strategies for preventing varix development and bleeding in HCV patients with advanced fibrosis.
  • Exploring novel therapeutic targets beyond PEG-IFN may be necessary.
  • Improved patient monitoring and risk stratification could enhance clinical outcomes.

More Related Videos

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices04:09

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices

Published on: June 13, 2025

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension04:00

Laparoscopic Splenectomy with Pericardial Devascularization for Hypersplenism and Esophageal Variceal Hemorrhage Due to Portal Hypertension

Published on: November 15, 2024

Related Concept Videos

Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...